17th european society on hypertension meeting milan 2007
Download
1 / 40

17th European Society on Hypertension Meeting Milan, 2007 - PowerPoint PPT Presentation


  • 179 Views
  • Uploaded on

17th European Society on Hypertension Meeting Milan, 2007. INGENIOUS HYPERCARE : RENAL PHENOTYPE. Josep Redon. MD, PhD, FAHA Hypertension Clinic. Internal Medicine Hospital Clinico. University of Valencia Spain.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about '17th European Society on Hypertension Meeting Milan, 2007' - chip


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
17th european society on hypertension meeting milan 2007 l.jpg

17th European Society on Hypertension MeetingMilan, 2007

INGENIOUS HYPERCARE:

RENAL PHENOTYPE

Josep Redon. MD, PhD, FAHA

Hypertension Clinic. Internal Medicine

Hospital Clinico. University of Valencia

Spain


Jrp b2 genetics genomics and proteomics on chronic kidney disease in hypertension l.jpg
JRP B2: Genetics, genomics and proteomics on chronic kidney disease in hypertension

Investigating the genetic, genomic and proteomic basis of susceptibility to renal damage (urinary albumin excretion and renal damage) in HTN patients

Creating a large database of several thousand patients in different European countries

Cross-sectional and follow-up investigations


Jrp b2 genetics genomics and proteomics on chronic kidney disease in hypertension objectives l.jpg
JRP B2: Genetics, genomics and proteomics on chronic kidney disease in hypertension: Objectives

To analyse genetic factors associated with renal phenotypes in hypertensive subjects: elevated urinary albumin excretion (microalbuminuria, proteinuria), reduced GFR, end-stage renal disease

To detect novel early markers of renal damage in hypertension by using proteomics and to examine their association with genetic markers


Jrp b2 genetics genomics and proteomics on chronic kidney disease in hypertension types of studies l.jpg
JRP B2: Genetics, genomics and proteomics on chronic kidney disease in hypertension: Types of studies

Family-based association study of renal phenotypes, conducted simultaneously in the A2, B2 and B3

Case-control studies of renal phenotypes in previously recruited hypertensives

Follow-up studies of renal phenotypes in preexisting cohorts and in the family study


Phenotypes for renal damage in hypertension l.jpg
Phenotypes for renal damage in hypertension: disease in hypertension: Types of studies

UAE

FG ml/min

years

months


Prevalence of renal damage in hypertension i demand project 927 subjects l.jpg
Prevalence of renal damage in hypertension. I-Demand project (927 subjects)

renal dysfunction: 38.5% of pts

microalbuminuria

N=233(25.3%)

eGFR 60 ml/min

N=221(24.0%)

134(14.5%)

99(10.7%)

122(13.2%)


Slide7 l.jpg
Seven-year incidence of ESRD according baseline creatinine clearance and proteinuria in general population

Proteinuria (+) Proteinuria (-)

1000

100

Cumulative Incidence of ESRD

per 1.000 screened in 7 yrs

10

1

0.1

0.01

0 15 30 45 60 75 90 105 120 135

Creatinine Clearance (ml/min)

From Iseki et al., 2004


Phenotypes for renal damage in hypertension gfr l.jpg
Phenotypes for renal damage in hypertension: GFR clearance and proteinuria in general population

eGFR

  • Cockroft-Gault Formula

  • (140- age) x body weight

  • (serum creatinine * 72)

  • * x 0.85 (if female)

  • MDRD Formula

  • 186 * serum creatinine -1.154 * age -0.203

  • * 0.742 (if female) * 1.210 (if AA)


Stages of chronic renal disease l.jpg
Stages of chronic renal disease clearance and proteinuria in general population


Prevalence of chronic renal failure in hypertension l.jpg
Prevalence of chronic renal failure in hypertension clearance and proteinuria in general population

Serum Cr eCrCl

> 1.4-1.5 mg/dl < 60 ml/min

(n)

HOT 18790 2.5% 12.3%

INSIGHT 6321 3.1 % 29.1%

HOPE 9173 10.5 % 36.4% **

H Clinico1539 5.3 % 17.5 % *


Creatinine and cardiovascular morbidity and mortality hope study l.jpg
Creatinine and cardiovascular morbidity and mortality. HOPE study

60

50

40

30

20

10

0

Primary

Myocardial

CV

Total

outcome

infarction

mortality

mortality

Creatinine <1,4 mg/dl

Creatinine >1,4mg/dl

Mann et al. Ann Intern Med 2001


Cardiovascular risk and creatinine values 1 5 mg dl hot study l.jpg

RR study

4

Cardiovascular risk and creatinine values >1.5 mg/dl. HOT study

3

2

1

0

Stroke

Total mortality

CV events

MI

CV mortality

Adapted from Ruilope et al, JASN 2001


Cardiovascular disease and probability of gfr decline the aric study l.jpg
Cardiovascular disease and probability of GFR decline. The ARIC study

Elsaved et al. Arch Intern Med 2007


Relationship between serum levels of creatinine and creatinine clearance l.jpg
Relationship between serum levels of creatinine and creatinine clearance

Miravalles, Rodicio (data onfile)


Formulans to estimate the gfr l.jpg
Formulans to estimate the GFR creatinine clearance

eGFR

  • Cockroft-Gault Formula

  • (140- age) x body weight

  • (serum creatinine * 72)

  • * x 0.85 (if female)

  • MDRD Formula

  • 186 * serum creatinine -1.154 * age -0.203

  • * 0.742 (if female) * 1.210 (if AA)


Relationship between mdrd and cockcroft gault formulas to estimate renal function l.jpg
Relationship between MDRD and Cockcroft-Gault formulas to estimate renal function

eGFR (ml/min/1.73m2)

Creatinine clearance (ml/min)

Miravalles, Rodicio (data onfile)


Relationship between two methods to estimate gfr mdrd formula and i talamate l.jpg
Relationship between two methods to estimate GFR: MDRD formula and I-talamate

Iodo-talamate

MDRD

Rule et al. Ann InternMed 2004


Gfr and standarized rates of hospitalization and cardiovascular events l.jpg
GFR and standarized rates of hospitalization and cardiovascular events

Kaiser Permanent Renal Registry

Go, A. S. et al. N Engl J Med 2004


Association of egfr and cystatin c with risk for death in elderly without chronic kidney disease l.jpg
Association of eGFR, and cystatin C with risk for death in elderly without chronic kidney disease

Shlipak et al. Ann InternMed 2006


Relationship between serum cystatin c and creatinine clearance l.jpg
Relationship between serum cystatin C and creatinine clearance

ROC curves to detect patients with GFR 60 – 90 mL/min

Cystatin C

0.671 (0.576 – 0.756)

Creatinine

0.578 (0.481 – 0.675)

Miravalles, Rodicio (data onfile)


Measuring gfr in the jrp a2 b2 and b3 i l.jpg
Measuring GFR in the JRP A2, B2 and B3 (I) clearance

  • MDRD formula in each of the centres

  • Creatininewillbemeasured in thecoordinating centre with a standarizedmethod and GFR willberecalculated

  • Cystatin C willbemeasured in thecoordinating centre



Prevalence of microalbuminuria according bp categories nahnes iii l.jpg
Prevalence of microalbuminuria according BP categories. NAHNES III

80

men women

70

60

56

55

50

Prevalence of albuminuria, %

40

35

31

30

21

20

16

14

12

12

8

10

7

5

0

optimal normal high normal stage 1 stage 2 stage 3

from Jones, et al. 2003


Natural history of microalbuminuria l.jpg
Natural history of microalbuminuria NAHNES III

Non-insulin resistant

60

60

Nephrosclerosis

50

40

Microalbuminuria

percentage (%)

30

Insulin-resistant

20

10

0

Time x BP

Redon et al. Curr Hypertens Rep 2007


Changes in uae categories according the uae level and the presence of treatment at the begining l.jpg
Changes in UAE categories according the UAE level and the presence of treatment at the begining

from Pascual, et al. J Hypertens 2006


Uae and risk of cardiovascular and non cardiovascular mortality l.jpg
UAE and risk of cardiovascular and non-cardiovascular mortality

60

Hillege et al Circulation 2000


Urinary albumin excretion and cardiovascular mortality nahnes ii l.jpg
Urinary albumin excretion and cardiovascular mortality. NAHNES II

1.00

0.75

0.50

0.25

0.00

50

55

60

65

70

75

80

85

<30 mg/dL, n=8528

30-299 mg/dL, n=196

300 mg/dL, n=62

Cumulative CV disease mortality

Age (yr)

Muntner et al. JASN 2002


Microalbuminuria and gfr changes overtime the prevend study l.jpg
Microalbuminuria and GFR changes overtime. The PREVEND study NAHNES II

Microalbuminuria

10

5

0

Delta creatinine clearance (ml/min per 4 year)

-5

-10

-15

1

10

100

1000

Urinary albumin excretion (mg/24hr)

Verhave et al. JASN 2003


Passage metabolization and excretion of albumin in the urine l.jpg

Filtration NAHNES II

Reabsorption

Degradation

Tubular cells

Back-leak

Back-leak

Passage, metabolization and excretion of albumin in the urine

Total albumin (IMRA and non-IMRA), fragments


Methods to measure albumin in urine l.jpg
Methods to measure albumin in urine NAHNES II

  • Antibodyrecognisablealbumin

    • Immunoassays (RIA, nephelometry)

  • Albuminnotdetectedbyimmunoassays

    • HPLC, precipitation

  • Peptidefragments

    • Spectrophotometry


  • Slide31 l.jpg

    Circadian NAHNES IIvariability of UAE in essentialhypertension

    1000

    100

    Night UAE (µg/min)

    10

    1

    1

    10

    100

    1000

    Day UAE (µg/min)

    Redón et al, MedClin, 1995


    Slide32 l.jpg

    Intraindividual NAHNES IIvariability of UAE measurements

    1000

    100

    First day

    24-hours (µg/min)

    10

    HTA

    DM tipo 1

    1

    1

    10

    100

    1000

    Second day 24 hours (µg/min)

    Redón et al, MedClin 1995


    Slide33 l.jpg

    UAE: NAHNES IIsamples and units of measurement

    Urine sample

    Units


    Slide34 l.jpg

    UAE: NAHNES IIsamples and units of measurement

    Urine sample

    Units


    Urinary albumin stability over time in ideal conditions 4 c and protected from light l.jpg
    Urinary albumin stability over time NAHNES IIin ideal conditions: 4ºC and protected from light

    Percentage

    of positives

    who still positive

    Percentage

    of negatives

    who still negative

    Correlation

    coefficient

    Day

    Agreement


    Urinary albumin measurement by using ria and hplc l.jpg
    Urinary albumin measurement by NAHNES IIusing RIA and HPLC



    Measuring uae in the jrp a2 b2 and b3 i l.jpg
    Measuring UAE in the JRP A2, B2 and B3 (I) albumin: RIA and HPLC

    • Firstvoidingurine in themorning

    • 3 differentdays

    • Measurementswithnephelometrie and simultaneousexamination of sediment (ordisptick) in each of the centres

    • 5 aliquotstostorefrozen at -20º at least (maintain at 4º out of light untilfrozen , recomendable no more than 4 hours)

    • Samplesfrozenshouldbesenttothecoordinating center (each 3 or 6 months)


    Measuring uae in the jrp a2 b2 and b3 and the others ii l.jpg
    Measuring UAE in the JRP A2, B2 and B3 (and the others) (II) albumin: RIA and HPLC

    • Measurements of albumin (nephrelometrie, HPLC) and creatinine

    • UAE willbeanalyzed as qualitative and quantitativetraits

    • Measurement of othermarkers (oxidative stress)

    • Proteomics in a smallsample (withspecialrequirementsforurinecollection and storage)


    Risk for esrd according bp categories in the kaiser permanent register 21 year follow up l.jpg
    Risk for ESRD according BP categories in the Kaiser Permanent Register (21-year follow-up)

    70

    men women

    aRR 4.25

    60

    50

    aRR 3.88

    aRR 3.86

    Age-adjusted ESRD rates

    per 100000 person-yrs

    40

    30

    aRR 2.59

    20

    aRR 1.98

    aRR 1.62

    10

    0

    <120/80

    ≥210/120

    130-139/85-89

    140-159/90-99

    120-129/80-84

    180-209/110-119

    160-179/100-109

    Blood pressure category

    from Hsu, et al. 2005


    ad